Sign in →

Test ID: BRUTA Brucella Total Antibody Confirmation, Agglutination, Serum

Reporting Name

Brucella Ab, Agglutination, S

Useful For

Diagnosis of brucellosis

Clinical Information

Brucella species are facultative intracellular, gram-negative bacilli that cause brucellosis in humans. Human disease is likely acquired by contact with animals infected with the organism (Brucella abortus, Brucella suis, Brucella melitensis, and occasionally Brucella canis) either by direct contact or by ingestion of meat or milk. The signs and symptoms associated with brucellosis may include fever, night sweats, chills, weakness, malaise, headache, and anorexia. The physical examination may reveal lymphadenopathy and hepatosplenomegaly. A definitive diagnosis of brucellosis is made by recovering the organism from bone marrow, blood, fluid (including urine), or tissue specimens.

 

In cases of suspected brucellosis, serology may assist in the diagnosis and play a supplementary role in routine culture. Antibodies to Brucella species may not become detectable until 1 to 2 weeks following the onset of symptoms, so serum specimens collected during acute disease may be negative by serology in patients with brucellosis. If serology is performed, the Centers for Disease Control and Prevention currently recommends that specimens testing positive or equivocal for IgG or IgM by a screening enzyme immunoassay be confirmed by a Brucella-specific agglutination method.

Interpretation

The Centers for Disease Control and Prevention recommends that specimens testing positive or equivocal for IgG or IgM by a screening enzyme immunoassay (EIA) be confirmed by a Brucella-specific agglutination method.

 

Titers below 1:80 are seen in normal, healthy populations. Titers of 1:80 or greater are often considered clinically significant (1); however, a 4-fold or greater increase in titers between acute and convalescent phase sera is required to diagnose acute infection.

 

Positive results by a screening EIA that are not confirmed by Brucella-specific agglutination may represent false-positive screening results. If clinically indicated, a new specimen should be tested after 7 to 14 days.

Report Available

2 to 7 days

Day(s) Performed

Wednesday, Friday

Clinical Reference

1. Welch RJ, Litwin CM. A comparison of Brucella IgG and IgM ELISA assays with agglutination methodology. J Clin Lab Anal. 2010;24(3):160-162

2. Gunes H, Dogan M False-positivity in diagnosis of brucellosis associated with Rev-1 vaccine. Libyan J Med. 2013:8:10.3402/ljm.v8i0.20417

3. Stoddard RA. Detection of Brucella spp antibodies. In: Leber AL, Burnham CD, eds. Clinical Microbiology Procedures Handbook. 5th ed. AMS Press; 2023:section13.3.3

Method Name

Agglutination

Specimen Type

Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Reference Values

<1:80

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86622

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BRUTA Brucella Ab, Agglutination, S 19053-8

 

Result ID Test Result Name Result LOINC Value
8112 Brucella Ab, Agglutination, S In Process

Forms

If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.

Mayo Clinic Laboratories | Neurology Catalog Additional Information:

mml-CNS-Infections, mml-Pediatric